Prognostic influence of fibroblast growth factor 23 on the course of coronary heart disease in patients with chronic kidney disease

Objective: to study the prognostic impact of the level of fibroblast growth factors 23 on coronary heart disease depending on the stage of chronic kidney disease. Materials and methods:  the study included 108 patients with coronary heart disease (CHD), stable angina (stress), functional class 1–3, chronic kidney disease (CKD) C1–C4, average age was 67,62±12,51 years (55 men and 53 women). The level of fibroblast growth factor 23 was assessed using the Biomedica FGF 23 multimatrix enzyme-linked immunosorbent assay. After 12 months of follow-up, the presence of a cumulative endpoint including the occurrence of acute coronary syndrome, stroke, transient ischemic attack, heart failure and death. Differences in data and correlations between them were considered statistically significant at p<0.05. Results: the developed prognostic model to determine the likelihood of cardiovascular complications in patients with coronary artery disease and CKD found that the FGF 23 level is equal to 27.9 with a sensitivity of 62.7% and specificity of 62.5% to distinguish patients with ischemic heart disease and CKD in whom a cumulative endpoint will occur over 12 months of follow-up. Conclusions: to identify patients at high risk of cardiovascular complications in coronary artery disease and CKD, it is advisable to use determination of FGF 23 level.

1. Reznik E.V., Nikitin I.G. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019;9(1):5-22. (In Russ.). DOI: 10.20514/2226-6704-2019-9-1-5-22.

2. Batra J, Buttar RS, Kaur P, Kreimerman J, Melamed ML. FGF-23 and cardiovascular disease: review of literature. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):423-429. DOI: 10.1097/MED.0000000000000294

3. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) DOI: 10.15829/1560-4071-2020-4076

4. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. Erratum in: Ann Intern Med. 2011;155(6):408. PMID: 19414839; PMCID: PMC2763564.DOI: 10.7326/0003-4819-150-9-200905050-00006

5. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622-627. DOI: 10.1053/j.ajkd.2010.02.337

6. Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82. (In Russ.) DOI: 10.24884/1561-6274-2021-25-5-10-82

7. Tuñón J, Fernández-Fernández B, Carda R, Pello AM, Cristóbal C, Tarín N, et al. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. Diabetes Metab Res Rev. 2016;32(7):685-693. DOI: 10.1002/dmrr.2787

8. Deo R, Katz R, de Boer IH, Sotoodehnia N, Kestenbaum B, Mukamal KJ, et al. Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study. Am J Kidney Dis. 2015;66(1):40-46. DOI: 10.1053/j.ajkd.2014.10.025

9. Lang F, Leibrock C, Pandyra AA, Stournaras C, Wagner CA, Föller M. Phosphate Homeostasis, Inflammation and the Regulation of FGF-23. Kidney Blood Press Res. 2018;43(6):1742-1748. DOI: 10.1159/000495393

10. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592. DOI: 10.1056/NEJMoa0706130

11. Scialla JJ, Parekh RS, Eustace JA, Astor BC, Plantinga L, Jaar BG, et al. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. Am J Nephrol. 2015;42(1):25-34. DOI: 10.1159/000438999

12. Koller L, Kleber ME, Brandenburg VM, Goliasch G, Richter B, Sulzgruber P, et al. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2015;8(6):1059-1067. DOI: 10.1161/CIRCHEARTFAILURE.115.002341

13. Zheng S, Wang C, Yan H, Xu M, Du Y. Fibroblast growth factor-23 as a biomarker of adverse outcomes in patients with coronary artery disease: a meta-analysis. Biomarkers. 2022;27(4):299-305. DOI: 10.1080/1354750X.2022.2046857